---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Glycine-Proline-Glutamate analogs"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Glycine-Proline-Glutamate analogs. Topics: Trofinetide: FDA-approved indication, formulations, and weight-based dosing; Trofinetide: class and rationale as a glycine-proline-glutamate analog; LAVENDER phase 3 trial: design and co-primary endpoints in the prescribing information; LAVENDER phase 3 trial: co-primary efficacy results at week 12; 10 further topics. 14 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/glycine-proline-glutamate-analogs"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Glycine-Proline-Glutamate analogs

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Glycine-Proline-Glutamate Analogs

<a id="topic-2.2.2.1.1-1"></a>

### Trofinetide: FDA-approved indication, formulations, and weight-based dosing

> “DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.”
> “Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food.”
> “Oral solution: 200 mg/mL of a pink to red, strawberry flavored solution. For oral solution: 5,000 mg, 6,000 mg, or 8,000 mg of white, off-white to pinkish powder with strawberry flavor, packaged in individual packets.”
> “The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

| Patient weight | Recommended dosage |
| --- | --- |
| 9 kg to less than 12 kg | “5,000 mg twice daily” |
| 12 kg to less than 20 kg | “6,000 mg twice daily” |
| 20 kg to less than 35 kg | “8,000 mg twice daily” |
| 35 kg to less than 50 kg | “10,000 mg twice daily” |
| 50 kg or more | “12,000 mg twice daily” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### Trofinetide: class and rationale as a glycine-proline-glutamate analog

> “Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

<a id="topic-2.2.2.1.1-3"></a>

### LAVENDER phase 3 trial: design and co-primary endpoints in the prescribing information

> “The efficacy of DAYBUE for the treatment of Rett syndrome was established in a 12-week randomized, double-blind, placebo-controlled study in patients with Rett syndrome 5 to 20 years of age (Study 1; NCT04181723).”
> “Patients were randomized to receive DAYBUE (N=93) or matching placebo (N=94) for 12 weeks.”
> “The co-primary efficacy measures were change from baseline after 12 weeks of treatment in the total score of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) score.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### LAVENDER phase 3 trial: co-primary efficacy results at week 12

| Measure | Trofinetide (N=93) | Placebo (N=94) |
| --- | --- | --- |
| RSBQ mean baseline score (SE) | “43.7 (1.21)” | “44.5 (1.26)” |
| RSBQ mean week 12 score (SE) | “39.9 (1.38)” | “42.8 (1.42)” |
| RSBQ LS mean change from baseline to week 12 (SE) | “-4.9 (0.94)” | “-1.7 (0.90)” |
| CGI-I mean week 12 score (SE) | “3.5 (0.08)” | “3.8 (0.06)” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

| Endpoint | Trofinetide-placebo treatment difference, LS mean (95% CI) | p-value |
| --- | --- | --- |
| RSBQ total score change from baseline | “-3.2 (-5.7, -0.6)” | “0.018” |
| CGI-I score at week 12 | “-0.3 (-0.5, -0.1)” | “0.003” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-5"></a>

### LAVENDER phase 3 trial: effect sizes, key secondary endpoint, and disposition

> “For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was −4.9 versus −1.7 (P = 0.0175; Cohen’s d effect size, 0.37), and LSM Clinical Global Impression–Improvement at week 12 was 3.5 versus 3.8 (P = 0.0030; effect size, 0.47).”
> “For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant–Toddler Checklist Social Composite score was −0.1 versus −1.1 (P = 0.0064; effect size, 0.43).”
> “155 participants (82.9%) completed the study (trofinetide, n = 70 (75.3%); placebo, n = 85 (90.4%))”
> “Eighteen participants withdrew due to a TEAE (trofinetide, n = 16 (17.2%); placebo, n = 2 (2.1%)), with diarrhea being the primary TEAE leading to discontinuation (trofinetide, n = 12 (12.9%))”

Source: [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)

<a id="topic-2.2.2.1.1-6"></a>

### LAVENDER phase 3 trial: adverse reactions in the prescribing information

| Adverse reaction | Trofinetide (N=93), % | Placebo (N=94), % |
| --- | --- | --- |
| Diarrhea | “82” | “20” |
| Vomiting | “29” | “12” |
| Fever | “9” | “4” |
| Seizure | “9” | “6” |
| Anxiety | “8” | “1” |
| Decreased appetite | “8” | “2” |
| Fatigue | “8” | “2” |
| Nasopharyngitis | “5” | “1” |

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### Trofinetide: warnings for diarrhea, weight loss, and vomiting

> “In Study 1 [see Clinical Studies (14)] and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy.”
> “In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE.”
> “In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss.”
> “Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE.”
> “Eighteen patients (19%) receiving DAYBUE had adverse reactions that led to withdrawal from the study. The most common adverse reaction leading to discontinuation of treatment with DAYBUE was diarrhea (15%).”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-8"></a>

### LILAC open-label extension: 40-week safety and efficacy

> “Females with Rett syndrome aged 5-21 years received open-label treatment with trofinetide for 40 weeks.”
> “Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). Diarrhea was the most common adverse event leading to treatment withdrawal (21.4%).”
> “The Rett Syndrome Behaviour Questionnaire mean score (standard error) improvement from the LAVENDER baseline to week 40 in LILAC was -7.3 (1.62) and -7.0 (1.61) for participants treated with trofinetide and placebo in LAVENDER, respectively.”

Source: [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/)

<a id="topic-2.2.2.1.1-9"></a>

### LILAC-2 open-label extension: 32-month safety and efficacy

> “In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45).”
> “Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.”

Source: [Percy et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39025065/)

<a id="topic-2.2.2.1.1-10"></a>

### DAFFODIL open-label study: girls aged 2 to 4 years

> “DAFFODIL was a phase 2/3, open-label study of trofinetide consisting of two treatment periods (12 weeks [period A] and ∼21 months [period B]).”
> “Fifteen participants were enrolled. Overall, the most common TEAEs were diarrhea (80.0%) and vomiting (53.3%), which were mild or moderate in severity. Steady-state exposure at clinical doses fell within the target exposure range.”

Source: [Percy et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043705/)

> “Use of DAYBUE or DAYBUE STIX in patients 2 to 4 years of age is supported by evidence from Study 1 and pharmacokinetic and safety data in 15 pediatric patients 2 to 4 years of age treated with DAYBUE”
> “Safety and effectiveness in pediatric patients less than 2 years of age have not been established.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.2.2.1.1-11"></a>

### LOTUS real-world study: dosing, caregiver-reported benefit, and diarrhea

> “Overall, 227 caregivers participated in this follow‐up. The median trofinetide dose at week 1 was 36.0% of the target dose and increased to over 80% by week 10 onwards; 55.2% of patients took the full trofinetide recommended daily dose.”
> “The incidence of diarrhea varied from weeks 1 to 12 (23%–50%) and months 4 to 12 (26%–38%); most reports of diarrhea were contained inside the patient's diaper.”

Source: [Cosand et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875184/)

<a id="topic-2.2.2.1.1-12"></a>

### Expert consensus: trofinetide as first-line therapy and titration

> “Two rounds of assessments were completed by 25 respondents in each round, resulting in agreement ≥ 75% being reached across the final statement set. The consensus supports trofinetide as the standard of care for eligible patients with early initiation and an individualized approach to titration to maximize efficacy and tolerability.”
> “Agreement (88%–100%) across statements 1–2 and 5–7 supports trofinetide as first‐line therapy in the standard of care for eligible patients with RTT aged ≥ 2 years”
> “To minimize the impact of side effects, this consensus supports initiation at 5–10 mL (1000–2000 mg) BID or 25%–50% of the recommended weight‐banded dose BID and then titrate carefully at 5 mL (1000 mg) increase every 1–2 weeks based on tolerance.”
> “Respondents supported maintaining treatment with trofinetide for at least 6 months post titration to determine efficacy”

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="topic-2.2.2.1.1-13"></a>

### Expert consensus: selected statements and overall agreement

| Consensus statement | Overall agreement |
| --- | --- |
| “Trofinetide should be part of the standard of care for RTT individuals at least 2 years of age, as indicated” | “88%” |
| “Trofinetide is not typically initiated at the full weight‐banded dose” | “96%” |
| “Consider discontinuing all constipation medications prior to initiating trofinetide” | “84%” |
| “The healthcare provider should adapt the titration schedule first before introducing additional medications, such as loperamide, to manage diarrhea” | “80%” |
| “Trofinetide can be safely discontinued without tapering” | “96%” |

Source: [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)

<a id="topic-2.2.2.1.1-14"></a>

### European Union authorization: neurobehavioural symptoms, age 5 years and older

> “Daybu is a medicine used for the treatment of neurobehavioural symptoms of Rett syndrome in adults and children aged 5 years and older.”
> “The Agency considered that although these improvements were small, they were relevant in the context of a rare and serious disorder such as Rett syndrome.”
> “Daybu received a marketing authorisation valid throughout the EU on 20 August 2026.”

Source: [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu)

Additional sources: [ClinicalTrials.gov NCT04181723](https://clinicaltrials.gov/study/NCT04181723); [ClinicalTrials.gov NCT04279314](https://clinicaltrials.gov/study/NCT04279314); [ClinicalTrials.gov NCT04776746](https://clinicaltrials.gov/study/NCT04776746); [ClinicalTrials.gov NCT04988867](https://clinicaltrials.gov/study/NCT04988867); [Neul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35149233/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
